Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan
Our aims were to determine the clinical impact of oral valganciclovir (VGCV) in infants aged ≤2 months with congenital cytomegalovirus (CMV) disease and evaluate the efficacy of VGCV when initiated beyond the neonatal period. The multicenter, single-arm, open-label clinical trial was conducted in Ja...
Main Authors: | Ichiro Morioka, Yasumasa Kakei, Takashi Omori, Kandai Nozu, Kazumichi Fujioka, Naoto Takahashi, Tetsushi Yoshikawa, Hiroyuki Moriuchi, Yoshinori Ito, Akira Oka |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/13/3582 |
Similar Items
-
Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment
by: Yuka Torii, et al.
Published: (2023-01-01) -
Efficacy of Low Dose Valganciclovir Prophylaxis for Cytomegalovirus Infection in Kidney Transplantation
by: Ümit Özçelik, et al.
Published: (2020-01-01) -
Refractory ulcerative colitis complicated by cytomegalovirus infection successfully treated with valganciclovir
by: Tiziana Larussa, et al.
Published: (2012-11-01) -
Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
by: Arindam Singha, et al.
Published: (2021-04-01) -
Role of oral valganciclovir in sick preterm with cytomegalovirus virus infection and ventilation dependence
by: Anumodan Gupta, et al.
Published: (2019-01-01)